Going Generic: Big Brands Poised To Lose Marketing Exclusivity In The US In 2019
Going Generic: Big Brands Poised To Lose Marketing Exclusivity In The US In 2019
$200.00
2019 should be a big year for the generics and biosimilars industries, as a sizable number of blockbuster drugs are losing their market exclusivity. Find out which drugs will see their first generic and biosimilar versions this year and what the repercussions will likely be.
Author: Jessica Merrill
Publisher: Scrip
- Description
A number of blockbuster drugs are due to see their first generic versions hitting the market in 2019, as biosimilars of major brands are also being launched. Go deeper into the biosimilars and generics that will premiere this year, a lineup that includes generic versions of blockbusters like Restasis, Lyrica, Advair, and Sensipar, and biosimilars of Avastin, Herceptin, and Rituxan. Find out from Scrip how 2019 is shaping up to be huge for both the biosimilars and generics industries.
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Paying for Pharmaceutical Value: The Problem of a One-Size-Fits-All Definit... 
Sign up to the